Oxymorphone
Numorphan, Opana (oxymorphone) is a small molecule pharmaceutical. Oxymorphone was first approved as Opana on 1982-01-01. It is used to treat pain in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oxymorphone hydrochloride
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
opana | New Drug Application | 2012-01-13 |
oxymorphone hydrochloride | ANDA | 2023-04-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Oxymorphone Hydrochloride, Opana Er, Endo Pharms | |||
8871779 | 2029-11-22 | DP | |
7851482 | 2029-07-10 | DP | |
8808737 | 2027-06-21 | U-1598, U-3085 | |
8192722 | 2025-09-15 | DP | |
8114383 | 2024-08-08 | DP | |
8075872 | 2023-11-20 | DP | |
8309060 | 2023-11-20 | DP | |
7276250 | 2023-02-04 | DP | U-826 |
8309112 | 2023-02-04 | DP | |
8309122 | 2023-02-04 | DP | |
8329216 | 2023-02-04 | DP |
HCPCS
Code | Description |
---|---|
J2410 | Injection, oxymorphone hcl, up to 1 mg |
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | OXYMORPHONE |
INN | oxymorphone |
Description | Oxymorphone is a morphinane alkaloid. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5 |
Identifiers
PDB | — |
CAS-ID | 76-41-5 |
RxCUI | 7814 |
ChEMBL ID | CHEMBL963 |
ChEBI ID | 7865 |
PubChem CID | 5284604 |
DrugBank | DB01192 |
UNII ID | 9VXA968E0C (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Oxymorphone - Amneal Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,557 documents
View more details
Safety
Black-box Warning
Black-box warning for: Oxymorphone hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
77 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more